Clinical Trials Logo

Clinical Trial Summary

Observational, retrospective and prospective, analytical study. Data will be collected from medical records and/or contact with physicians and institutions (secondary collection and data). Patients who are included retrospectively or prospectively will be followed up during the data collection period to assess treatments and survival. No intervention is provided for in this protocol

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05184504
Study type Observational
Source Latin American Cooperative Oncology Group
Contact André Fay, MD
Phone +55 51 33845334
Email [email protected]
Status Not yet recruiting
Start date February 2022
Completion date March 2028

See also
  Status Clinical Trial Phase
Completed NCT00678392 - Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer Phase 3
Not yet recruiting NCT03129724 - Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib N/A
Terminated NCT01413607 - The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy Phase 4
Terminated NCT00091611 - Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer Phase 1
Terminated NCT02439008 - Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response N/A
Active, not recruiting NCT01688999 - Cabozantinib for Advanced Urothelial Cancer Phase 2
Completed NCT04933604 - LPN in Patients With High-complex Renal Tumors
Recruiting NCT05068180 - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients Phase 4
Recruiting NCT05119335 - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1/Phase 2
Terminated NCT02543645 - A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Phase 1
Terminated NCT01712685 - Imaging Studies of Kidney Cancer Using 18F-VM4-037 Phase 2
Terminated NCT00816686 - A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer Phase 1
Completed NCT00537056 - Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI N/A
Completed NCT00076011 - Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma Phase 2
Completed NCT00226980 - A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma Phase 2
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Recruiting NCT03160274 - Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Recruiting NCT03062410 - Quality of Life Assessment in Daily Clinical Oncology Practice for Patients With Advanced Renal Cell Carcinoma N/A
Completed NCT02924922 - Assessment of Oncological and Functional Outcomes After Robot Assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy N/A
Terminated NCT02386111 - A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma Phase 1